Literature DB >> 1962617

Opportunistic infections of the esophagus not responding to oral systemic antifungals in patients with AIDS: their frequency and treatment.

F Parente1, M Cernuschi, G Rizzardini, A Lazzarin, L Valsecchi, G Bianchi Porro.   

Abstract

To determine the spectrum of esophageal disease responsible for dysphagia/odynophagia in AIDS patients not responding to current oral antifungals, we studied 49 consecutive patients whose esophageal symptoms failed to improve after a minimum of 3 wk of therapy with oral ketoconazole or fluconazole. An esophageal candidiasis resistant to oral antifungals was the most frequent disease found (22 single infections and four mixed with viruses). Viral esophagitis was identified in 13 cases (eight herpes simplex virus and five cytomegalovirus), and an esophagitis of unknown origin was documented in two patients. Other causes of symptoms included peptic esophagitis (four cases), esophageal stenosis (two cases), and Kaposi's sarcoma of the esophagus (one patient). Most patients with esophageal opportunistic infection experienced prompt relief of symptoms and complete endoscopic resolution on the specific antifungal (amphotericin B or fluconazole iv) or antiviral (acyclovir or gancyclovir iv) therapy, with the exception of those with concomitant fungal and viral infection who responded poorly to treatment. We conclude that most AIDS patients with dysphagia/odynophagia who do not respond to oral antifungals have an opportunistic infection of the esophagus. Nevertheless, specific antifungal or antiviral therapy is worthwhile, because it will eradicate, at least temporarily, the causative pathogens in most such patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1962617

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  Diagnostic value of antigenemia assay for cytomegalovirus gastrointestinal disease in immunocompromised patients.

Authors:  Naoyoshi Nagata; Masao Kobayakawa; Takuro Shimbo; Kazufusa Hoshimoto; Tomoyuki Yada; Takuji Gotoda; Junichi Akiyama; Shinichi Oka; Naomi Uemura
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

3.  Natural history of HIV-associated esophageal disease in the era of protease inhibitor therapy.

Authors:  E J Bini; P L Micale; E H Weinshel
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

4.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

5.  Evaluating diagnosis and treatment of oral and esophageal candidiasis in Ugandan AIDS patients.

Authors:  M Ravera; A Reggiori; A M Agliata; R P Rocco
Journal:  Emerg Infect Dis       Date:  1999 Mar-Apr       Impact factor: 6.883

6.  In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.

Authors:  W Hundt; H Hofmann
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.